Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Microbial cell surface anionic components represent a diverse group of negatively charged molecules found on the exterior of bacteria, yeasts, and within the matrix of biofilms. In Gram-negative bacteria, the primary anionic component is lipopolysaccharide (LPS) in the outer membrane, while Gram-positive bacteria possess teichoic acids (lipoteichoic and wall teichoic acids) and a high proportion of anionic phospholipids like phosphatidylglycerol. Yeasts also display anionic surface characteristics through phosphorylated mannans in their cell walls and specific membrane lipids. In biofilms, the extracellular polymeric substance (EPS) matrix contains anionic polysaccharides and extracellular DNA, which contribute to the overall negative charge and structural stability of the community. These components are critical for maintaining structural integrity, regulating ion homeostasis, and facilitating adhesion to host surfaces. Because human cell membranes are predominantly zwitterionic (neutral), these anionic microbial surfaces serve as a selective therapeutic target for cationic antimicrobial agents, such as polymyxins, daptomycin, and antimicrobial peptides (AMPs). These drugs typically interact via electrostatic attraction, leading to membrane disruption, depolarization, and rapid cell death, making them effective against a broad spectrum of pathogens and drug-resistant strains.
Drugs targeting these components typically utilize electrostatic attraction between their cationic groups and the anionic microbial surface (e.g., LPS, teichoic acids, or phospholipids). This is followed by membrane insertion, which leads to physical disruption, pore formation, and depolarization of the cytoplasmic membrane, ultimately causing cell lysis and death.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Microbial cell surface anionic components.